Preferred Label : cyclohexanes;
MeSH definition : Six-carbon alicyclic hydrocarbons.;
Is substance : O;
Origin ID : D003510;
UMLS CUI : C0010568;
Allowable qualifiers
Automatic exact mappings (from CISMeF team)
Record concept(s)
Related MeSH Supplementary Concept(s)
- AC-186 [MeSH Supplementary Concept]
- AY 9928 [MeSH Supplementary Concept]
- CB65 [MeSH Supplementary Concept]
- CKD732 [MeSH Supplementary Concept]
- F 1394 [MeSH Supplementary Concept]
- KCG 1 [MeSH Supplementary Concept]
- KCG 10 [MeSH Supplementary Concept]
- NTE 122 [MeSH Supplementary Concept]
- Omite [MeSH Supplementary Concept]
- PB167 [MeSH Supplementary Concept]
- RK-805 [MeSH Supplementary Concept]
- S27847 [MeSH Supplementary Concept]
- TAI 998 [MeSH Supplementary Concept]
- URO-K10 [MeSH Supplementary Concept]
- V214w [MeSH Supplementary Concept]
- vesitan [MeSH Supplementary Concept]
Semantic type(s)
Six-carbon alicyclic hydrocarbons.
https://www.has-sante.fr/portail/jcms/c_2869665/fr/celsentri
2018
false
true
false
false
France
French
evaluation of the transparency committee
adolescent
child
adult
treatment outcome
HIV-1
hiv infections
hiv infections
CCR5 Receptor Antagonists
CCR5 Receptor Antagonists
Genotype drug resistance test
maraviroc
administration, oral
drug therapy, combination
selzentry
cyclohexanes
triazoles
cyclohexanes
triazoles
cyclohexanes
triazoles
Maraviroc
Maraviroc
Maraviroc
---
https://www.has-sante.fr/portail/jcms/c_2848372/fr/celsentri
https://www.has-sante.fr/portail/jcms/c_2848372/fr/celsentri-maraviroc-antiretroviral-antagoniste-du-recepteur-ccr5
2018
false
false
false
false
France
French
evaluation of the transparency committee
adolescent
child
adult
treatment outcome
guidelines for drug use
HIV-1
hiv infections
hiv infections
CCR5 Receptor Antagonists
CCR5 Receptor Antagonists
Genotype drug resistance test
maraviroc
selzentry
cyclohexanes
triazoles
cyclohexanes
triazoles
cyclohexanes
triazoles
Maraviroc
Maraviroc
---
https://pharmacomedicale.org/medicaments/par-specialites/item/autres-antiretroviraux
2016
false
false
false
France
French
drug information
hiv fusion inhibitors
hiv infections
enfuvirtide
maraviroc
CCR5 Receptor Antagonists
Raltegravir Potassium
raltegravir
HIV integrase inhibitors
anti-retroviral agents
peptide fragments
HIV envelope protein gp41
cyclohexanes
triazoles
Enfuvirtide
Maraviroc
---
http://www.has-sante.fr/portail/jcms/c_2561558/fr/celsentri
2015
false
false
false
France
French
evaluation of the transparency committee
cyclohexanes
triazoles
Maraviroc
---
https://reptox.cnesst.gouv.qc.ca/pages/fiche-complete.aspx?no_produit=205922&nom=1,4-bis+(Aminométhyl)cyclohexane
Canada
toxicological data sheet
cyclohexanes
Cyclohexane
---
https://reptox.cnesst.gouv.qc.ca/pages/fiche-complete.aspx?no_produit=12377&nom=Cyclohexane
Canada
toxicological data sheet
Cyclohexane
cyclohexanes
---
http://www.inrs.fr/accueil/produits/bdd/doc/fichetox.html?refINRS=FT%2017
France
French
cyclohexanes
cyclohexanes
cyclohexanes
cyclohexanes
cyclohexanes
occupational exposure
occupational diseases
reference values
Cyclohexane
guidelines
toxicological data sheet
---
https://www.ema.europa.eu/medicines/human/EPAR/Celsentri
2012
false
United Kingdom
English
French
CCR5 Receptor Antagonists
CCR5 Receptor Antagonists
syndication feed
hiv infections
hiv fusion inhibitors
cyclohexanes
tablets
administration, oral
adult
HIV-1
acquired immunodeficiency syndrome
drug therapy, combination
cyclohexanes
cyclohexanes
triazoles
triazoles
hiv fusion inhibitors
hiv fusion inhibitors
treatment outcome
cyclohexanes
triazoles
hiv fusion inhibitors
drug interactions
drug approval
drug labeling
pregnancy
triazoles
triazoles
cyclohexanes
hiv fusion inhibitors
drug resistance, viral
triazoles
cyclohexanes
hiv fusion inhibitors
drug evaluation, preclinical
breast feeding
maraviroc
summary of product characteristics
drug evaluation
package leaflet
Maraviroc
Maraviroc
---
https://www.ema.europa.eu/medicines/human/EPAR/Starlix
2011
false
United Kingdom
French
English
syndication feed
Product containing nateglinide (medicinal product)
Product containing precisely nateglinide 60 milligram/1 each conventional release
oral tablet (clinical drug)
Product containing precisely nateglinide 120 milligram/1 each conventional release
oral tablet (clinical drug)
Product containing precisely nateglinide 180 milligram/1 each conventional release
oral tablet (clinical drug)
Contraindications, Procedure
hypoglycemic agents
cyclohexanes
hypoglycemic agents
hypoglycemic agents
cyclohexanes
cyclohexanes
drug evaluation, preclinical
drug labeling
diabetes mellitus, type 2
drug approval
hypoglycemic agents
cyclohexanes
drug interactions
pregnancy
breast feeding
hypoglycemic agents
treatment outcome
drug therapy, combination
drug evaluation
cyclohexanes
phenylalanine
tablets
administration, oral
hypoglycemic agents
cyclohexanes
hypoglycemic agents
cyclohexanes
adult
aged
nateglinide
drug evaluation
summary of product characteristics
package leaflet
Contraindications, Drug
Nateglinide
---
http://www.inrs.fr/accueil/dms/inrs/PDF/bdd-demeter/DEM-074/DEM%20074.pdf
2010
toxicological data sheet
cyclohexanes
Cyclohexane
---
http://unt-ori2.crihan.fr/unspf/2010_Lyon1_Radix_StereochimieReactivite.pdf
2010
true
false
true
France
stereoisomerism
problems and exercises
education, pharmacy
chemistry, organic
cyclohexanes
molecular conformation
---
http://www.has-sante.fr/portail/jcms/c_865545/tests-de-determination-du-tropisme-du-vih-1-dans-le-cadre-du-traitement-avec-un-antagoniste-du-recepteur-a-chimiokines-ccr5
http://www.has-sante.fr/portail/jcms/c_870286/rapport-tests-de-tropisme
2009
true
France
French
CCR5 Receptor Antagonists
HIV-1
viral tropism
cyclohexanes
triazoles
hiv infections
anti-retroviral agents
hiv fusion inhibitors
phenotype
genotype
health technology assessment
treatment outcome
Maraviroc
---
https://www.cadth.ca/sites/default/files/pdf/E0036_Maraviroc_cetap_fr.pdf
https://www.cadth.ca/sites/default/files/pdf/E0036_Maraviroc_cetap_e.pdf
2007
false
Canada
French
English
CCR5 Receptor Antagonists
CCR5 Receptor Antagonists
CCR5 Receptor Antagonists
triazoles
hiv infections
HIV-1
hiv fusion inhibitors
cyclohexanes
drug resistance, multiple, viral
treatment outcome
adult
Evidence-Based medicine
cyclohexanes
cyclohexanes
triazoles
triazoles
hiv fusion inhibitors
hiv fusion inhibitors
canada
randomized controlled trials as topic
maraviroc
drug evaluation
Maraviroc
Maraviroc
Maraviroc
---
https://www.ema.europa.eu/medicines/human/EPAR/Trazec
2007
United Kingdom
English
French
syndication feed
Contraindications, Procedure
drug therapy, combination
treatment outcome
drug evaluation
tablets
administration, oral
diabetes mellitus, type 2
cyclohexanes
phenylalanine
cyclohexanes
hypoglycemic agents
cyclohexanes
hypoglycemic agents
adult
aged
cyclohexanes
hypoglycemic agents
drug interactions
pregnancy
breast feeding
cyclohexanes
hypoglycemic agents
cyclohexanes
cyclohexanes
hypoglycemic agents
hypoglycemic agents
drug approval
hypoglycemic agents
drug labeling
nateglinide
drug evaluation
summary of product characteristics
package leaflet
Contraindications, Drug
Nateglinide
---
https://centres-antipoison.net/wp-content/uploads/2017/08/rapport_cyclohexane_CCTV_2007.pdf
2007
France
scientific and technical information
poison control centers
Cyclohexane
cyclohexanes
censuses
---
http://www.has-sante.fr/portail/display.jsp?id=c_400917
http://www.has-sante.fr/portail/display.jsp?id=c_247821
http://www.has-sante.fr/portail/display.jsp?id=c_626373
2006
France
French
fatty acids, unsaturated
sesquiterpenes
cyclohexanes
orphan drug production
enterocytozoon
microsporidiosis
diarrhea
aids-related opportunistic infections
fumagillin
cyclohexanes
fatty acids, unsaturated
sesquiterpenes
evaluation of the transparency committee
---